COVID-19与肾小球疾病
COVID-19是系统性疾病,肾脏是感染靶器官之一,肾损伤发生率可高达40%。多种肾小球疾病被报道与COVID-19相关,其中塌陷性肾小球病最为常见,高风险APOL1基因型是主要风险因素。短期结局总体较差,发病率和死亡率高,需进一步研究长期结局。
要点
- COVID-19患者肾损伤常见,可发生于高达40%的患者。
- 塌陷性肾小球病是COVID-19相关肾小球疾病中最常见的类型,高风险APOL1基因型是主要风险因素。
- COVID-19患者肾小球疾病的治疗具有挑战性,需谨慎权衡免疫抑制的风险与获益。
核心结论
- 肾小球疾病在COVID-19中频繁报道且有合理机制解释的,可能与COVID-19相关;罕见报道且无已知合理机制的,可能不相关。
- 塌陷性肾小球病(CG)是迄今为止最常见的类型,其与COVID-19的关联类似HIV与CG,由此新提出「COVID-19相关肾病」或「COVAN」的术语。
- 短期结局各异但总体较差,发病率和死亡率高,未来需研究长期结局以增进对COVID-19相关肾小球疾病的理解。
研究设计与样本
- 综述类文献,检索范围原文未报告。
主要发现
- 肾损伤常见,可发生于高达40%的患者。
- 塌陷性肾小球病是迄今为止最常见的肾小球疾病,高风险APOL1基因型是COVAN患者的主要风险因素。
- 足细胞病、膜性肾病(MN)、寡免疫复合物新月体性肾小球肾炎(GN)和血栓性微血管病(TMA)也有报道。
- 在移植肾中,CG仍是最常见的肾小球病理类型。
- 患者通常在COVID-19诊断时或诊断后不久表现为急性肾损伤(AKI)或尿液检查异常。
关键数值与推荐
- 肾损伤可发生于高达40%的COVID-19患者。
临床怎么用
- COVID-19患者肾小球疾病的治疗具有挑战性,提供者应谨慎考虑权衡免疫抑制的风险与获益,尤其是在活动性疾病患者中。
- 短期结局各异但总体较差,发病率和死亡率高。
- 未来需研究长期结局以增进对COVID-19相关肾小球疾病的理解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 is a systemic disease, and the kidney is one of the target organs of infection. Kidney injury is common and can occur in up to 40% of patients. Several glomerular diseases have been reported in association with COVID-19. Some are likely related to COVID-19 whereas many are likely coincidental. Glomerular diseases that are frequently reported in COVID-19 and have a plausible mechanistic explanation are likely to be related to COVID-19. In contrast, glomerular diseases that are seldom reported and have no known plausible mechanism, are likely to be unrelated. Collapsing glomerulopathy (CG) is by far the most prevalent. Its association with COVID-19, resembling HIV and CG, led to the newly proposed term "COVID-19 associated nephropathy" or "COVAN." High-risk APOL1 genotypes are the major risk factor in COVAN patients. Podocytopathy, membranous nephropathy (MN), pauci-immune crescentic glomerulonephritis (GN), and thrombotic microangiopathy (TMA) are also reported. In kidney allografts, CG remains the most common glomerular pathology. Patients typically present with acute kidney injury (AKI) or abnormal urinary findings at the time of or shortly after COVID-19 diagnosis. Treatment of glomerular disease in patients with COVID-19 is challenging. Providers should cautiously consider balancing risks and benefit of immunosuppression, particularly in patients with active diseases. Short-term outcomes vary but generally remain poor with high morbidity and mortality. Future study of long-term outcomes is needed to improve our understanding of glomerular disease associated with COVID-19.
引用
- Klomjit N, Zand L, Cornell LD, et al. COVID-19 and Glomerular Diseases. Kidney Int Rep. 2023. PMID: 37274308. doi:10.1016/j.ekir.2023.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。